ERBB2 and breast cancer: International guidelines currently recommend considering the addition of pertuzumab to trastuzumab and chemotherapy only in high-risk patients—namely, those who are node-positive and have HR− BC—thus limiting the role for this escalated treatment strategy in patients with HR+/HER2+ BC [6].